TY - JOUR
T1 - Impact of COVID-19 on cancer care in India
T2 - a cohort study
AU - National Cancer Grid of India
AU - Ranganathan, Priya
AU - Sengar, Manju
AU - Chinnaswamy, Girish
AU - Agrawal, Gaurav
AU - Arumugham, Rajkumar
AU - Bhatt, Rajiv
AU - Bilimagga, Ramesh
AU - Chakrabarti, Jayanta
AU - Chandrasekharan, Arun
AU - Chaturvedi, Harit Kumar
AU - Choudhrie, Rajiv
AU - Dandekar, Mitali
AU - Das, Ashok
AU - Goel, Vineeta
AU - Harris, Caleb
AU - Hegde, Sujai Kolnadguthu
AU - Hulikal, Narendra
AU - Joseph, Deepa
AU - Kantharia, Rajesh
AU - Khan, Azizullah
AU - Kharde, Rohan
AU - Khattry, Navin
AU - Lone, Maqbool M.
AU - Mahantshetty, Umesh
AU - Malhotra, Hemant
AU - Menon, Hari
AU - Mishra, Deepti
AU - Nair, Rekha A.
AU - Pandya, Shashank J.
AU - Patni, Nidhi
AU - Pautu, Jeremy
AU - Pavamani, Simon
AU - Pradhan, Satyajit
AU - Thammineedi, Subramanyeshwar Rao
AU - Selvaluxmy, G.
AU - Sharan, Krishna
AU - Sharma, B. K.
AU - Sharma, Jayesh
AU - Singh, Suresh
AU - Srungavarapu, Gowtham Chandra
AU - Subramaniam, R.
AU - Toprani, Rajendra
AU - Raman, Ramanan Venkat
AU - Badwe, Rajendra Achyut
AU - Pramesh, C. S.
N1 - Funding Information:
The pandemic has had considerable impact on cancer research globally. Organisations such as the US Food and Drug Administration and the European Medicines Association issued guidelines for cancer research during the pandemic. 25,26 The key measures suggested were to reduce the use of immunosuppressive treatments and minimise hospital visits solely for research purposes. As a result, several cancer centres stopped accrual on ongoing trials, delayed the initiation of new projects, and amended protocols to minimise participant risk. Such changes are likely to delay the results of these projects. In the long term, the economic recession and diversion of funding to COVID-19 research will impact research funding for other diseases, including cancer. Cancer Research UK and the Canadian Cancer Society have had to decrease their budgets for research funding, 27 and a joint Indo-UK research grant initiative 28 has been withdrawn as a consequence.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/7
Y1 - 2021/7
N2 - Background: The COVID-19 pandemic has disrupted health-care systems, leading to concerns about its subsequent impact on non-COVID disease conditions. The diagnosis and management of cancer is time sensitive and is likely to be substantially affected by these disruptions. We aimed to assess the impact of the COVID-19 pandemic on cancer care in India. Methods: We did an ambidirectional cohort study at 41 cancer centres across India that were members of the National Cancer Grid of India to compare provision of oncology services between March 1 and May 31, 2020, with the same time period in 2019. We collected data on new patient registrations, number of patients visiting outpatient clinics, hospital admissions, day care admissions for chemotherapy, minor and major surgeries, patients accessing radiotherapy, diagnostic tests done (pathology reports, CT scans, MRI scans), and palliative care referrals. We also obtained estimates from participating centres on cancer screening, research, and educational activities (teaching of postgraduate students and trainees). We calculated proportional reductions in the provision of oncology services in 2020, compared with 2019. Findings: Between March 1 and May 31, 2020, the number of new patients registered decreased from 112 270 to 51 760 (54% reduction), patients who had follow-up visits decreased from 634 745 to 340 984 (46% reduction), hospital admissions decreased from 88 801 to 56 885 (36% reduction), outpatient chemotherapy decreased from 173634 to 109 107 (37% reduction), the number of major surgeries decreased from 17 120 to 8677 (49% reduction), minor surgeries from 18 004 to 8630 (52% reduction), patients accessing radiotherapy from 51 142 to 39 365 (23% reduction), pathological diagnostic tests from 398 373 to 246 616 (38% reduction), number of radiological diagnostic tests from 93 449 to 53 560 (43% reduction), and palliative care referrals from 19 474 to 13 890 (29% reduction). These reductions were even more marked between April and May, 2020. Cancer screening was stopped completely or was functioning at less than 25% of usual capacity at more than 70% of centres during these months. Reductions in the provision of oncology services were higher for centres in tier 1 cities (larger cities) than tier 2 and 3 cities (smaller cities). Interpretation: The COVID-19 pandemic has had considerable impact on the delivery of oncology services in India. The long-term impact of cessation of cancer screening and delayed hospital visits on cancer stage migration and outcomes are likely to be substantial. Funding: None. Translation: For the Hindi translation of the abstract see Supplementary Materials section.
AB - Background: The COVID-19 pandemic has disrupted health-care systems, leading to concerns about its subsequent impact on non-COVID disease conditions. The diagnosis and management of cancer is time sensitive and is likely to be substantially affected by these disruptions. We aimed to assess the impact of the COVID-19 pandemic on cancer care in India. Methods: We did an ambidirectional cohort study at 41 cancer centres across India that were members of the National Cancer Grid of India to compare provision of oncology services between March 1 and May 31, 2020, with the same time period in 2019. We collected data on new patient registrations, number of patients visiting outpatient clinics, hospital admissions, day care admissions for chemotherapy, minor and major surgeries, patients accessing radiotherapy, diagnostic tests done (pathology reports, CT scans, MRI scans), and palliative care referrals. We also obtained estimates from participating centres on cancer screening, research, and educational activities (teaching of postgraduate students and trainees). We calculated proportional reductions in the provision of oncology services in 2020, compared with 2019. Findings: Between March 1 and May 31, 2020, the number of new patients registered decreased from 112 270 to 51 760 (54% reduction), patients who had follow-up visits decreased from 634 745 to 340 984 (46% reduction), hospital admissions decreased from 88 801 to 56 885 (36% reduction), outpatient chemotherapy decreased from 173634 to 109 107 (37% reduction), the number of major surgeries decreased from 17 120 to 8677 (49% reduction), minor surgeries from 18 004 to 8630 (52% reduction), patients accessing radiotherapy from 51 142 to 39 365 (23% reduction), pathological diagnostic tests from 398 373 to 246 616 (38% reduction), number of radiological diagnostic tests from 93 449 to 53 560 (43% reduction), and palliative care referrals from 19 474 to 13 890 (29% reduction). These reductions were even more marked between April and May, 2020. Cancer screening was stopped completely or was functioning at less than 25% of usual capacity at more than 70% of centres during these months. Reductions in the provision of oncology services were higher for centres in tier 1 cities (larger cities) than tier 2 and 3 cities (smaller cities). Interpretation: The COVID-19 pandemic has had considerable impact on the delivery of oncology services in India. The long-term impact of cessation of cancer screening and delayed hospital visits on cancer stage migration and outcomes are likely to be substantial. Funding: None. Translation: For the Hindi translation of the abstract see Supplementary Materials section.
UR - http://www.scopus.com/inward/record.url?scp=85108806933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108806933&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(21)00240-0
DO - 10.1016/S1470-2045(21)00240-0
M3 - Article
C2 - 34051879
AN - SCOPUS:85108806933
SN - 1470-2045
VL - 22
SP - 970
EP - 976
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 7
ER -